{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:26:20Z","timestamp":1791357980389,"version":"4.3.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13046-019-1085-3","type":"journal-article","created":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T10:04:16Z","timestamp":1550484256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":239,"title":["Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma"],"prefix":"10.1186","volume":"38","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaochao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,18]]},"reference":[{"key":"1085_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11060-016-2318-3","volume":"131","author":"A Darlix","year":"2017","unstructured":"Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella Branger D, Mathieu-Daud\u00e9 H, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2017;131:525\u201346.","journal-title":"J Neurooncol"},{"key":"1085_CR2","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"QT Ostrom","year":"2015","unstructured":"Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol. 2015;17:iv1\u2013iv62.","journal-title":"Neuro Oncol"},{"issue":"1","key":"1085_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-011-0738-7","volume":"107","author":"M Koshy","year":"2012","unstructured":"Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neuro-Oncol. 2012;107(1):207\u201312.","journal-title":"J Neuro-Oncol"},{"key":"1085_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJB, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC- NCIC trial. Lancet Oncol. 2009;10:459\u201366.","journal-title":"Lancet Oncol."},{"issue":"3","key":"1085_CR5","first-page":"196","volume":"9","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. Clin Med Insights Oncol. 2005;9(3):196\u20137.","journal-title":"Clin Med Insights Oncol"},{"key":"1085_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature14432","volume":"523","author":"A Louveau","year":"2015","unstructured":"Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523:337\u201341.","journal-title":"Nature"},{"key":"1085_CR7","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1158\/1078-0432.CCR-14-0832","volume":"20","author":"PE Fecci","year":"2014","unstructured":"Fecci PE, Heimberger AB, Sampson JH. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014;20:5620\u20139.","journal-title":"Clin Cancer Res"},{"issue":"7725","key":"1085_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","volume":"562","author":"H Ledford","year":"2018","unstructured":"Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562(7725):20\u20131.","journal-title":"Nature"},{"issue":"1","key":"1085_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13046-018-0937-6","volume":"37","author":"A Rotte","year":"2018","unstructured":"Rotte A, D\u2019Orazi G, Bhandaru M. Nobel committee honors tumor immunologists. J Exp Clin Cancer Res. 2018;37(1):262.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1085_CR10","first-page":"5","volume":"38","author":"CR Shen","year":"2015","unstructured":"Shen CR, Chen YS. Immune checkpoint blockade therapy: the 2014 tang prize in biopharmaceutical science. Biom J. 2015;38(1):5.","journal-title":"Biom J"},{"issue":"1","key":"1085_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-018-0777-4","volume":"37","author":"F Xu","year":"2018","unstructured":"Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1):110.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"1085_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1586\/14737140.2015.1074862","volume":"15","author":"E Faghfuri","year":"2015","unstructured":"Faghfuri E, Faramarzi MA, Nikfar S, Abdollahi M. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma. Expert Rev Anticancer Ther. 2015;15(9):981\u201393.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1085_CR13","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1093\/neuonc\/nou307","volume":"17","author":"AS Berghoff","year":"2015","unstructured":"Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology. 2015;17:1064\u201375.","journal-title":"Neuro-Oncology"},{"issue":"2","key":"1085_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/neuonc\/nov172","volume":"18","author":"EK Nduom","year":"2016","unstructured":"Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology. 2016;18(2):195\u2013205.","journal-title":"Neuro-Oncology"},{"key":"1085_CR15","doi-asserted-by":"crossref","unstructured":"Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, et al. Targeting PD-1 and TIM-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic\/tumor vaccines. J Immunother. 2016;39(4):171\u201380.","DOI":"10.1097\/CJI.0000000000000122"},{"key":"1085_CR16","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.1158\/1078-0432.CCR-14-0514","volume":"20","author":"DA Wainwright","year":"2014","unstructured":"Wainwright DA, Chang AL, Dey M, Balyasnikova IV, Kim CK, Tobias A, et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res. 2014;20:5290\u2013301.","journal-title":"Clin Cancer Res"},{"key":"1085_CR17","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res. 2016;4:124\u201335.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1085_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"S Dai","year":"2014","unstructured":"Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1\/PD-ls pathway and autoimmune diseases. Cell Immunol. 2014;290(1):72\u20139.","journal-title":"Cell Immunol"},{"key":"1085_CR19","doi-asserted-by":"crossref","unstructured":"Victor TS, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer[J]. Nature. 2015;520(7547):373\u20137.","DOI":"10.1038\/nature14292"},{"key":"1085_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/ni1443","volume":"8","author":"AH Sharpe","year":"2007","unstructured":"Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol. 2007;8:239\u201345.","journal-title":"Nat Immunol"},{"key":"1085_CR21","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u201384.","journal-title":"Lancet Oncol."},{"key":"1085_CR22","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064\u201374.","journal-title":"Clin Cancer Res"},{"key":"1085_CR23","doi-asserted-by":"crossref","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","DOI":"10.1056\/NEJMoa1603702"},{"issue":"4","key":"1085_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PPO.0000000000000063","volume":"20","author":"S Gettinger","year":"2014","unstructured":"Gettinger S, Herbst RS. B7-h1\/pd-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 2014;20(4):281\u20139.","journal-title":"Cancer J"},{"issue":"5","key":"1085_CR25","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1093\/neuonc\/nox208","volume":"20","author":"A Omuro","year":"2018","unstructured":"Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of checkmate 143. Neuro-Oncology. 2018;20(5):674\u201386.","journal-title":"Neuro-Oncology"},{"issue":"53","key":"1085_CR26","doi-asserted-by":"publisher","first-page":"91779","DOI":"10.18632\/oncotarget.21586","volume":"8","author":"AC Filley","year":"2017","unstructured":"Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, checkmate-143: the game is not over yet. Oncotarget. 2017;8(53):91779\u201394.","journal-title":"Oncotarget"},{"key":"1085_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, Narayanan M, Ford E. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Investig. 2013;31:140\u20134.","journal-title":"Cancer Investig"},{"issue":"8","key":"1085_CR28","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into t cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399.","journal-title":"Nat Rev Immunol"},{"key":"1085_CR29","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1084\/jem.20100643","volume":"207","author":"K Sakuishi","year":"2010","unstructured":"Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207:2187\u201394.","journal-title":"J Exp Med"},{"issue":"6","key":"1085_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, Deimling AV, Figarella-Branger D, Cavenee WK, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320.","journal-title":"Acta Neuropathol"},{"issue":"1","key":"1085_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40169-018-0211-8","volume":"7","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Trans Med. 2018;7(1):33.","journal-title":"Clin Trans Med"},{"key":"1085_CR32","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98\u2013110.","journal-title":"Cancer Cell"},{"issue":"1","key":"1085_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32(1):42\u201356.","journal-title":"Cancer Cell"},{"issue":"21","key":"1085_CR34","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1158\/1078-0432.CCR-17-2769","volume":"24","author":"RA Buerki","year":"2018","unstructured":"Buerki RA, Chheda ZS, Okada H. Immunotherapy of primary brain tumors: facts and hopes. Clin Cancer Res. 2018;24(21):5198\u2013205.","journal-title":"Clin Cancer Res"},{"key":"1085_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124\u20138.","journal-title":"Science"},{"key":"1085_CR36","doi-asserted-by":"crossref","unstructured":"Johnson DB, Frampton GM, Rioth MJ, Yusko E, Xu Y, Guo X, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res. 2016;4(11):959\u2013967.","DOI":"10.1158\/2326-6066.CIR-16-0143"},{"issue":"6230","key":"1085_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374.","journal-title":"Science"},{"issue":"7463","key":"1085_CR38","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415\u201321.","journal-title":"Nature"},{"issue":"22","key":"1085_CR39","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1093\/jnci\/85.22.1836","volume":"85","author":"J Kuratsu","year":"1993","unstructured":"Kuratsu J, Yoshizato K, Yoshimura T, Leonard EJ, Takeshima H, Ushio Y. Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst. 1993;85(22):1836\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1085_CR40","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1535-7163.MCT-09-0734","volume":"9","author":"J Wei","year":"2010","unstructured":"Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010;9(1):67\u201378.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"1085_CR41","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.3390\/cancers5041379","volume":"5","author":"BJ Ahn","year":"2013","unstructured":"Ahn BJ, Pollack IF, Okada H. Immune-checkpoint blockade and active immunotherapy for glioma. Cancers. 2013;5(4):1379\u2013412.","journal-title":"Cancers"},{"issue":"4","key":"1085_CR42","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425\u201337.","journal-title":"J Clin Invest"},{"issue":"6","key":"1085_CR43","doi-asserted-by":"publisher","first-page":"e1320626","DOI":"10.1080\/2162402X.2017.1320626","volume":"6","author":"JP Layer","year":"2017","unstructured":"Layer JP, Kronm\u00fcller MT, Quast T, van den Boorn-Konijnenberg D, Effern M, Hinze D, et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. Oncoimmunology. 2017;6(6):e1320626.","journal-title":"Oncoimmunology"},{"key":"1085_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3389\/fonc.2015.00153","volume":"5","author":"P Perng","year":"2015","unstructured":"Perng P, Lim M. Immunosuppressive mechanisms of malignant gliomas: parallels at non-CNS sites. Front Oncol. 2015;5:153.","journal-title":"Front Oncol"},{"issue":"2","key":"1085_CR45","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1093\/carcin\/bgr289","volume":"33","author":"J Zhang","year":"2012","unstructured":"Zhang J, Sarkar S, Cua R, Zhou Y, Hader W, Yong VW. A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2\/CCR2\/interleukin-6 axis. Carcinogenesis. 2012;33(2):312\u20139.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1085_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2009.05.006","volume":"17","author":"I Yang","year":"2010","unstructured":"Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci. 2010;17(1):6\u201310.","journal-title":"J Clin Neurosci"},{"key":"1085_CR47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ctrv.2018.06.016","volume":"69","author":"M Simonelli","year":"2018","unstructured":"Simonelli M, Persico P, Perrino M, Zucali PA, Navarria P, Pessina F, et al. Checkpoint inhibitors as treatment for malignant gliomas: \u201ca long way to the top\u201d. Cancer Treat Rev. 2018;69:121\u201331.","journal-title":"Cancer Treat Rev"},{"key":"1085_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1084\/jem.188.2.287","volume":"188","author":"AM Thornton","year":"1998","unstructured":"Thornton AM, Shevach EM. CD4+CD25+ immunoreg- ulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287\u201396.","journal-title":"J Exp Med"},{"key":"1085_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1084\/jem.20020642","volume":"196","author":"D Dieckmann","year":"2002","unstructured":"Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G. Human CD4(+)CD25(+) regulatory, contact- dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells. J Exp Med. 2002;196:247\u201353.","journal-title":"J Exp Med"},{"key":"1085_CR50","doi-asserted-by":"publisher","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","volume":"17","author":"EK Nduom","year":"2015","unstructured":"Nduom EK, Weller M, Heimberger AB. Immunosuppressive mechanisms in glioblastoma. Neuro-Oncology. 2015;17:vii9\u2013vii14.","journal-title":"Neuro-Oncology"},{"key":"1085_CR51","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1002\/eji.200323966","volume":"33","author":"NO Camara","year":"2003","unstructured":"Camara NO, Sebille F, Lechler RI. Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation. Eur J Immunol. 2003;33:3473\u201383.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1085_CR52","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2017","unstructured":"Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2017;29(1):71\u201383.","journal-title":"Ann Oncol"},{"key":"1085_CR53","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature. 2017;545:60\u20135.","journal-title":"Nature"},{"key":"1085_CR54","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355:1423\u20137.","journal-title":"Science"},{"key":"1085_CR55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/2326-6066.CIR-14-0239","volume":"3","author":"JR Webb","year":"2015","unstructured":"Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely Coexpressed on Prognostically favorable intraepithelial CD8 T cells in human ovarian Cancer. Cancer Immunol Res. 2015;3:926\u201335.","journal-title":"Cancer Immunol Res"},{"key":"1085_CR56","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/mi.2009.112","volume":"3","author":"O Akbari","year":"2010","unstructured":"Akbari O, Stock P, Singh AK, Lombardi V, Lee WL, Freeman GJ, et al. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. Mucosal Immunol. 2010;3:81\u201391.","journal-title":"Mucosal Immunol"},{"key":"1085_CR57","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00262-010-0946-6","volume":"60","author":"W Maes","year":"2011","unstructured":"Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 2011;60:153\u201360.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1085_CR58","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1089\/dna.2013.2306","volume":"33","author":"S Han","year":"2014","unstructured":"Han S, Feng S, Xu L, Shi W, Wang X, Wang H, et al. Tim-3 on peripheral CD4+ and CD8+ T cells is involved in the development of glioma. DNA Cell Biol. 2014;33(4):245\u201350.","journal-title":"DNA Cell Biol"},{"issue":"3","key":"1085_CR59","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3892\/ol.2016.4142","volume":"11","author":"Z Liu","year":"2016","unstructured":"Liu Z, Han H, He X, Li S, Wu C, Yu C, et al. Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma. Oncol Lett. 2016;11(3):1829\u201334.","journal-title":"Oncol Lett"},{"issue":"8","key":"1085_CR60","doi-asserted-by":"publisher","first-page":"e1328339","DOI":"10.1080\/2162402X.2017.1328339","volume":"6","author":"G Li","year":"2017","unstructured":"Li G, Wang Z, Zhang C, Liu X, Cai J, Wang Z, et al. Molecular and clinical characterization of TIM- 3 in glioma through 1,024 samples. Oncoimmunology. 2017;6(8):e1328339.","journal-title":"Oncoimmunology"},{"issue":"2","key":"1085_CR61","doi-asserted-by":"publisher","first-page":"e000213","DOI":"10.1136\/esmoopen-2017-000213","volume":"2","author":"C Granier","year":"2017","unstructured":"Granier C, De Guillebon ED, Blanc C, Roussel H, Badoual C, Colin E, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213.","journal-title":"ESMO Open"},{"issue":"9","key":"1085_CR62","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1111\/cas.12986","volume":"107","author":"Y He","year":"2016","unstructured":"He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, et al. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. Cancer Sci. 2016;107(9):1193\u20137.","journal-title":"Cancer Sci"},{"key":"1085_CR63","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","volume":"22","author":"DH Munn","year":"2005","unstructured":"Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D, et al. GCN2 kinase in T cells mediates prolifera- tive arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity. 2005;22:633\u201342.","journal-title":"Immunity"},{"key":"1085_CR64","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77:6795\u2013811.","journal-title":"Cancer Res"},{"issue":"5","key":"1085_CR65","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.21873\/anticanres.11551","volume":"37","author":"P Sordillo","year":"2017","unstructured":"Sordillo P, Sordillo L, Helson L. The kynurenine pathway: a primary resistance mechanism in patients with glioblastoma. Anticancer Res. 2017;37(5):2159\u201371.","journal-title":"Anticancer Res"},{"key":"1085_CR66","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/nm.2092","volume":"16","author":"Y Wang","year":"2010","unstructured":"Wang Y, Liu H, McKenzie G, Witting PK, Stasch JP, Hahn M, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16:279\u201385.","journal-title":"Nat Med"},{"key":"1085_CR67","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20130066","volume":"210","author":"RB Holmgaard","year":"2013","unstructured":"Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3- dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med. 2013;210:1389\u2013402.","journal-title":"J Exp Med"},{"issue":"1","key":"1085_CR68","first-page":"129","volume":"35","author":"Y Shindo","year":"2015","unstructured":"Shindo Y, Yoshimura K, Kuramasu A, Watanabe Y, Ito H, Kondo T, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res. 2015;35(1):129\u201336.","journal-title":"Anticancer Res"},{"key":"1085_CR69","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fonc.2015.00117","volume":"5","author":"T Bartkowiak","year":"2015","unstructured":"Bartkowiak T, Curran MA. 4-1BB agonists: multi-potent Potentiators of tumor immunity. Front Oncol. 2015;5:117.","journal-title":"Front Oncol"},{"issue":"18","key":"1085_CR70","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","volume":"23","author":"AW Tolcher","year":"2017","unstructured":"Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, et al. Phase Ib study of Utomilumab (PF-05082566), a 4-1BB\/CD137 agonist, in combination with Pembrolizumab (MK-3475) in patients with advanced solid tumors. Clin Cancer Res. 2017;23(18):5349\u201357.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1085_CR71","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1600-065X.2009.00766.x","volume":"229","author":"M Croft","year":"2009","unstructured":"Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev. 2009;229(1):173\u201391.","journal-title":"Immunol Rev"},{"issue":"3\u20134","key":"1085_CR72","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.cytogfr.2008.04.003","volume":"19","author":"T So","year":"2008","unstructured":"So T, Lee SW, Croft M. Immune regulation and control of regulatory T cells by OX40 and 4-1BB. Cytokine Growth Factor Rev. 2008;19(3\u20134):253\u201362.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"10","key":"1085_CR73","doi-asserted-by":"crossref","first-page":"5261","DOI":"10.4049\/jimmunol.151.10.5261","volume":"151","author":"DM Calderhead","year":"1993","unstructured":"Calderhead DM, Buhlmann JE, van den Eertwegh AJ, Claassen E, Noelle RJ, Fell HP. Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions. J Immunol. 1993;151(10):5261\u201371.","journal-title":"J Immunol"},{"issue":"4","key":"1085_CR74","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-2567.2004.01917.x","volume":"112","author":"MW Munks","year":"2004","unstructured":"Munks MW, Mourich DV, Mittler RS, Weinberg AD, Hill AB. 4-1BB and OX40 stimulation enhance CD8 and CD4 T- cell responses to a DNA prime, poxvirus boost vaccine. Immunology. 2004;112(4):559\u201366.","journal-title":"Immunology"},{"key":"1085_CR75","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/0161-5890(87)90122-2","volume":"24","author":"DJ Paterson","year":"1987","unstructured":"Paterson DJ, Jefferies WA, Green JR, Brandon MR, Corthesy P, Puklavec M, et al. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol. 1987;24:1281\u201390.","journal-title":"Mol Immunol"},{"key":"1085_CR76","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.4049\/jimmunol.161.12.6510","volume":"161","author":"I Gramaglia","year":"1998","unstructured":"Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J Immunol. 1998;161:6510\u20137.","journal-title":"J Immunol"},{"key":"1085_CR77","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/eji.200535637","volume":"36","author":"CA Huddleston","year":"2006","unstructured":"Huddleston CA, Weinberg AD, Parker DC. OX40 (CD134) engagement drives differentiation of CD4\u00fe T cells to effector cells. Eur J Immunol. 2006;36:1093\u2013103.","journal-title":"Eur J Immunol"},{"issue":"20","key":"1085_CR78","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","volume":"23","author":"DJ Messenheimer","year":"2017","unstructured":"Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, et al. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clin Cancer Res. 2017;23(20):6165\u201377.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1085_CR79","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","volume":"5","author":"RK Shrimali","year":"2017","unstructured":"Shrimali RK, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, et al. Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis. Cancer Immunol Res. 2017;5(9):755\u201366.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1085_CR80","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3322\/caac.21358","volume":"67","author":"FG Herrera","year":"2016","unstructured":"Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice. CA Cancer J Clin. 2016;67(1):65.","journal-title":"CA Cancer J Clin"},{"key":"1085_CR81","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, et al. Low- dose irradiation programs macrophage differentiation to an iNOS(1)\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589\u2013602.","journal-title":"Cancer Cell"},{"key":"1085_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3109\/09553002.2010.518208","volume":"87","author":"M Cao","year":"2011","unstructured":"Cao M, Cabrera R, Xu Y, Liu C, Nelson D. Different radiosensitivity of CD4(1)CD25(1) regulatory T cells and effector T cells to low dose gamma irradiation in vitro. Int J Radiat Biol. 2011;87:71\u201380.","journal-title":"Int J Radiat Biol"},{"issue":"2","key":"1085_CR83","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1085_CR84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/1078-0432.CCR-15-1535","volume":"23","author":"JE Kim","year":"2015","unstructured":"Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, et al. Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas. Clin Cancer Res. 2015;23(1):124\u201336.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1085_CR85","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","volume":"24","author":"E Ladomersky","year":"2018","unstructured":"Ladomersky E, Zhai L, Lenzen A, Lauing KL, Qian J, Scholtens DM, et al. IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma. Clin Cancer Res. 2018;24(11):2559\u201373.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1085_CR86","first-page":"796","volume":"19","author":"JP Antonios","year":"2017","unstructured":"Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, et al. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1\/PD-L1 mechanism in glioblastoma. Neuro-Oncology. 2017;19(6):796\u2013807.","journal-title":"Neuro-Oncology"},{"issue":"7738","key":"1085_CR87","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234\u20139.","journal-title":"Nature"},{"issue":"1","key":"1085_CR88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13046-018-0751-1","volume":"37","author":"L Aurisicchio","year":"2018","unstructured":"Aurisicchio L, Pallocca M, Ciliberto G, Palombo F. The perfect personalized cancer therapy: cancer vaccines against neoantigens. J Exp Clin Cancer Res. 2018;37(1):86.","journal-title":"J Exp Clin Cancer Res"},{"key":"1085_CR89","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.4049\/jimmunol.167.3.1137","volume":"167","author":"CA Piccirillo","year":"2001","unstructured":"Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167:1137\u201340.","journal-title":"J Immunol"},{"key":"1085_CR90","doi-asserted-by":"publisher","first-page":"5213","DOI":"10.4049\/jimmunol.172.9.5213","volume":"172","author":"SG Zheng","year":"2004","unstructured":"Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-h, and IL-10. J Immunol. 2004;172:5213\u201321.","journal-title":"J Immunol"},{"issue":"5","key":"1085_CR91","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/neuonc\/nos014","volume":"14","author":"CA Crane","year":"2012","unstructured":"Crane CA, Ahn BJ, Han SJ, Parsa AT. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro-Oncology. 2012;14(5):584\u201395.","journal-title":"Neuro-Oncology"},{"key":"1085_CR92","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.biomaterials.2016.09.034","volume":"112","author":"Y Wang","year":"2017","unstructured":"Wang Y, Lin YX, Qiao SL, An HW, Ma Y, Qiao ZY, et al. Polymeric nanoparticles enable reversing macrophage in tumor microenvironment for immunotherapy. Biomaterials. 2017;112:153\u201363.","journal-title":"Biomaterials"},{"issue":"2","key":"1085_CR93","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","volume":"32","author":"D Saha","year":"2017","unstructured":"Saha D, Martuza RL, Rabkin SD. Macrophage polarization contributes to glioblastoma eradication by combination Immunovirotherapy and immune checkpoint blockade. Cancer Cell. 2017;32(2):253\u201367.","journal-title":"Cancer Cell"},{"key":"1085_CR94","first-page":"945","volume":"5","author":"J Han","year":"2015","unstructured":"Han J, Alvarez-Breckenridge CA, Wang QE, Wu Y. TGF-\u03b2 signaling and its targeting for glioma treatment. Am J Cancer Res. 2015;5:945\u201355.","journal-title":"Am J Cancer Res"},{"issue":"26","key":"1085_CR95","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"8","key":"1085_CR96","doi-asserted-by":"publisher","first-page":"8944","DOI":"10.18632\/oncotarget.6884","volume":"7","author":"J Zeng","year":"2016","unstructured":"Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX. Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget. 2016;7(8):8944\u201355.","journal-title":"Oncotarget"},{"issue":"1","key":"1085_CR97","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4132\/jptm.2016.08.31","volume":"51","author":"J Han","year":"2017","unstructured":"Han J, Hong Y, Lee YS. PD-L1 expression and combined status of PD-L1\/PD-1-positive tumor infiltrating mononuclear cell density predict prognosis in glioblastoma patients. J Pathol Transl Med. 2017;51(1):40\u20138.","journal-title":"J Pathol Transl Med"},{"issue":"19","key":"1085_CR98","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1200\/JCO.2016.66.6552","volume":"34","author":"E Bouffet","year":"2016","unstructured":"Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for Hypermutant glioblastoma Multiforme resulting from germline Biallelic mismatch repair deficiency. J Clin Oncol. 2016;34(19):2206\u201311.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1085_CR99","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1158\/2159-8290.CD-16-0575","volume":"6","author":"TM Johanns","year":"2016","unstructured":"Johanns TM, Miller CA, Dorward IG, Tsien C, Chang E, Perry A, et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 2016;6(11):1230\u20136.","journal-title":"Cancer Discov"},{"key":"1085_CR100","first-page":"2164","volume":"51","author":"AJ Ekstrand","year":"1991","unstructured":"Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res. 1991;51:2164\u201372.","journal-title":"Cancer Res"},{"key":"1085_CR101","first-page":"1383","volume":"60","author":"L Frederick","year":"2000","unstructured":"Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60:1383\u20137.","journal-title":"Cancer Res"},{"key":"1085_CR102","first-page":"4130","volume":"57","author":"CJ Wikstrand","year":"1997","unstructured":"Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res. 1997;57:4130\u201340.","journal-title":"Cancer Res"},{"key":"1085_CR103","doi-asserted-by":"publisher","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","volume":"91","author":"R Nishikawa","year":"1994","unstructured":"Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A. 1994;91:7727\u201331.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1085_CR104","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.mcn.2003.09.011","volume":"24","author":"JA Boockvar","year":"2003","unstructured":"Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, Bogler O, et al. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci. 2003;24:1116\u201330.","journal-title":"Mol Cell Neurosci"},{"key":"1085_CR105","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ijc.11566","volume":"108","author":"MW Pedersen","year":"2004","unstructured":"Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer. 2004;108:643\u201353.","journal-title":"Int J Cancer"},{"key":"1085_CR106","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1158\/1078-0432.CCR-04-1737","volume":"11","author":"AB Heimberger","year":"2005","unstructured":"Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11:1462\u20136.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1085_CR107","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1172\/JCI90644","volume":"127","author":"G Kohanbash","year":"2017","unstructured":"Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, et al. Isocitrate dehydrogenase mutations suppress STAT1and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425\u201337.","journal-title":"J Clin Invest"},{"issue":"10","key":"1085_CR108","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Borugeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Invest. 2018;128(10):4654\u201368.","journal-title":"J Clin Invest"},{"issue":"24","key":"1085_CR109","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1212\/WNL.0000000000002770","volume":"86","author":"W Cheng","year":"2016","unstructured":"Cheng W, Ren X, Zhang C, Cai J, Liu Y, Han S, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226\u201334.","journal-title":"Neurology"},{"issue":"3","key":"1085_CR110","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11060-016-2190-1","volume":"129","author":"DT Blumenthal","year":"2016","unstructured":"Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neuro-Oncol. 2016;129(3):453\u201360.","journal-title":"J Neuro-Oncol"},{"issue":"suppl 5","key":"1085_CR111","doi-asserted-by":"crossref","first-page":"v109","DOI":"10.1093\/annonc\/mdx366","volume":"28","author":"M Lim","year":"2017","unstructured":"Lim M, Omuro A, Vlahovic G, Reardon DA, Sahebjam S, Cloughesy T, et al. Nivolumab (nivo) in combination with radiotherapy (RT) \u00b1 temozolomide (TMZ): updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM). Ann Oncol. 2017;28(suppl 5):v109\u201321.","journal-title":"Ann Oncol"},{"key":"1085_CR112","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.biopha.2018.11.105","volume":"110","author":"N Yaghoubi","year":"2019","unstructured":"Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM, Hashemy SI. PD-1\/ PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 2019;110:312\u20138.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"1085_CR113","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1200\/JCO.2017.72.2850","volume":"36","author":"MK Callahan","year":"2018","unstructured":"Callahan MK, Kluger H, Postow MA, Segal NH, Lesokhin A, Atkins MB, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391\u20138.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1085_CR114","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"13","key":"1085_CR115","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","volume":"33","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1085_CR116","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","volume":"16","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Mazieres J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16(3):257\u201365.","journal-title":"Lancet Oncol"}],"container-title":["Journal of Experimental & Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1085-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1085-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T14:57:10Z","timestamp":1694617030000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1085-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,18]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1085"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1085-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,18]]},"assertion":[{"value":"7 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"87"}}